U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Showing 1 - 10 of 221 results

Status:
US Approved Rx (2017)
First approved in 2017

Class (Stereo):
CHEMICAL (ABSOLUTE)



Naldemedine (Symproic) is an opioid antagonist indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain. Naldemedine is an opioid antagonist with binding affinities for mu-, delta-, and kappa-opi...
Status:
US Approved Rx (2021)
First approved in 2015

Class (Stereo):
CHEMICAL (ABSOLUTE)



Eluxadoline, an orally active mixed μ opioid receptor (μOR) agonist δ opioid receptor (δOR) antagonist. Eluxadoline normalizes gastrointestinal (GI) transit and defecation under conditions of novel environment stress or post-inflammatory altered GI f...
Status:
US Approved Rx (2016)
First approved in 2008

Class (Stereo):
CHEMICAL (ABSOLUTE)



Methylnaltrexone, is a peripherally acting μ-opioid receptor antagonist that acts on the gastrointestinal tract to inhibit the opioid-induced decrease in gastric motility and transit time. It is used to treat opiate-induced constipation in adults wit...
Status:
US Approved Rx (2008)
First approved in 2008

Class (Stereo):
CHEMICAL (ABSOLUTE)


Conditions:

Tapentadol is the first US FDA-approved centrally acting analgesic having both μ-opioid receptor agonist and noradrenaline (norepinephrine) reuptake inhibition activity with minimal serotonin reuptake inhibition. Tapentadol is indicated for the manag...
Status:
US Approved Rx (2023)
First approved in 2008

Class (Stereo):
CHEMICAL (ABSOLUTE)



Alvimopan (LY246736, ADL 8-2698, trade name Entereg) is a potent, peripherally selective mu-opioid receptor antagonist. Alvimopan was developed by Adolor Corporation (now Cubist Pharmaceuticals) and GlaxoSmithKline for the treatment of postoperative ...
Status:
US Approved Rx (2020)
First approved in 1996

Class (Stereo):
CHEMICAL (ACHIRAL)


Conditions:

Remifentanil (marketed by Abbott as Ultiva) is a potent ultra short-acting synthetic opioid analgesic drug. It is given to patients during surgery to relieve pain and as an adjunct to an anaesthetic. ULTIVA is a µ-opioid agonist with rapid onset and ...
Status:
US Approved Rx (2022)
First approved in 1995

Class (Stereo):
CHEMICAL (ABSOLUTE)


Conditions:

Nalmefene is the first medication approved for alcoholism with the primary goal of reducing alcohol intake in an as needed approach. Nalmefene received a marketing authorization valid throughout the European Union on February 25, 2013 and is under de...
Status:
US Approved Rx (2011)
First approved in 1995

Class (Stereo):
CHEMICAL (RACEMIC)



Tramadol (sold under the brand name Ultram) is a narcotic analgesic proposed for moderate to severe pain. Tramadol and its O-desmethyl metabolite (M1) are selective, weak OP3-receptor agonists. Opiate receptors are coupled with G-protein receptors an...
Status:
US Approved Rx (1986)
First approved in 1986

Class (Stereo):
CHEMICAL (ACHIRAL)


Conditions:

Alfentanil is an opioid analgesic with a rapid onset of action. Alfentanil interacts predominately with the opioid mu-receptor. These mu-binding sites are discretely distributed in the human brain, spinal cord, and other tissues. In clinical settings...
Status:
US Approved Rx (2018)
First approved in 1984

Class (Stereo):
CHEMICAL (ACHIRAL)


Conditions:

Sufentanil is a synthetic opioid analgesic. Sufentanil interacts predominately with the opioid mu-receptor. These mu-binding sites are discretely distributed in the human brain, spinal cord, and other tissues. In clinical settings, sufentanil exerts ...